Tempest Therapeutics
TPST
42 hedge funds and large institutions have $12.9M invested in Tempest Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 21 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less capital invested
Capital invested by funds: $14.8M → $12.9M (-$1.97M)
18% less funds holding
Funds holding: 51 → 42 (-9)
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
67% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 21
77% less call options, than puts
Call options by funds: $47K | Put options by funds: $200K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$1.61M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$616K |
| 3 |
WG
Winton Group
London,
United Kingdom
|
+$317K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$275K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$54.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Bpifrance
Maisons Alfort, Cedex,
France
|
-$942K |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$492K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$410K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$355K |
| 5 |
HT
HAP Trading
New York
|
-$270K |
TPST Hedge Fund Activity: Q3 2020 in Review
42 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2020, worth a combined $12.9M — down 13% from $14.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TPST and 5 opened new positions — a net loss of 9 holders — while 21 trimmed existing stakes and 7 added.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $1.61M. The largest seller was Bpifrance, cutting an estimated $942K.
- 42 institutional investors held Tempest Therapeutics (TPST) as of Q3 2020, down from 51 in Q2 2020.
- Funds reported $12.9M of Tempest Therapeutics stock for Q3 2020, down 13% quarter-over-quarter.
- 5 funds opened new Tempest Therapeutics positions in Q3 2020 and 14 closed out, a net change of -9 holders.
- The largest Tempest Therapeutics buyer in Q3 2020 was Ghost Tree Capital, an estimated $1.61M added.
- The largest Tempest Therapeutics seller in Q3 2020 was Bpifrance, an estimated $942K sold.
Based on aggregated 13F filings for Q3 2020.